The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / The Benefits of Blood Money: OxyContin & Ethics

The Benefits of Blood Money: OxyContin & Ethics

March 18, 2019 • By Philip Seo, MD, MHS

  • Tweet
  • Email
Print-Friendly Version / Save PDF

On Feb. 9, 2019, protesters gathered at the Guggenheim Museum in New York City to lead a march down Fifth Avenue to the Metropolitan Museum of Art.1

You Might Also Like
  • Cigna to End OxyContin Painkiller Coverage, Signs Contract for Alternative
  • U.S. Appeals Court Ruling May Clear Barrier to Generic OxyContin
  • Washington State Sues OxyContin Maker Purdue Pharma
Explore This Issue
March 2019
Also By This Author
  • Adventures in Vaccinating

As a general rule, news from the world of art is not a topic discussed in these pages, but if you indulge me for just a little bit longer, I promise this will start to make sense.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The protest was organized in secret by Nan Goldin, an American photographer whose work has been featured in London by the Tate.2 The protestors entered the museum during the day, along with art patrons and tourists. Then, at 6:30 p.m., they announced their purpose. The protestors unfurled a large red banner embossed with black letters that proclaimed “200 dead each day.”3

A shower of fake prescriptions then fell on the heads of the unsuspecting patrons of the Guggenheim. The prescriptions were ostensibly signed by Richard Sackler of Purdue Pharma for a patient named Solomon R. Guggenheim.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The prescriptions were for OxyContin.

In place of instructions appeared a quotation from Mr. Sackler, the co-chair of Purdue Pharma: “If OxyContin is uncontrolled, it is highly likely that it will eventually be abused. … How substantially would it improve our sales?”3

1 in 5

Merriam-Webster defines compassion as a “sympathetic consciousness of others’ distress together with a desire to alleviate it.”4 It is an essential part of the human condition, and the prime reason many of us went to medical school.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

William Osler, of course, said it best: “The practice of medicine … is a life of … countless opportunities to comfort and help the weak hearted, and to raise up those that fall.”5

Compassion fatigue is what happens to us in the weeks following a tsunami in Southeast Asia, or at the end of a particularly bad clinic day. Compassion is not a limitless resource. Charles R. Figley, who developed the concept, described it thus:

We have not been directly exposed to the trauma scene, but we hear the story told with such intensity, or we hear similar stories so often, or we have the gift and curse of extreme empathy and we suffer. We feel the feelings of our clients. We experience their fears. We dream their dreams. Eventually, we lose a certain spark of optimism, humor, and hope. We tire.6

For those of us engaged in patient care, compassion fatigue is an occupational hazard. That said, we also experience it more broadly in our daily lives. In this era of the 24-hour news cycle, the drumbeat of depressing news is pervasive. It is no wonder that, on occasion, to certain stories, we become numb.

I think it’s even more surprising, therefore, that the story of opiate addiction in the U.S. still has the power to shock. In 1999, opiate overdose caused 16,849 deaths; in 2017, the number of deaths attributed opiate overdose was 70,237.7 Opiate overdose is now the leading cause of death of Americans under 50 years old.8 Opiate addiction has led to a decrease in the average life expectancy in the U.S.9 The odds of dying of an opiate overdose in the U.S. are now higher than the odds of dying in a car accident.10 In 2016, one in 65 deaths was related to opiates, higher than the number of deaths caused by hypertension or HIV/AIDS. Among adults between 25 and 34 years old, opiates are responsible for 1 in 5 deaths.11

It is also surprising how a single drug, OxyContin, became a major cause of opiate addiction in the U.S. Surprising, but not accidental. The manufacturer started with an unproved and unfounded claim that “delayed absorption as provided by OxyContin tablets is believed to reduce the abuse liability of a drug.”12 On the strength of that single claim, Purdue Pharma built an empire. In 2000, the U.S. Food and Drug Administration forced Purdue Pharma to remove that statement from its label, and in 2003, started to add multiple black box warnings about the risks associated with OxyContin’s use, but by then, the damage was done. Deaths due to narcotics had already started to surge.13

Pages: 1 2 3 4 | Single Page

Filed Under: Ethics, Opinion, Rheuminations Tagged With: Arthur M. Sackler Foundation, Dr. Mortimer and Theresa Sackler Foundation, opioid crisis, opioid use disorders, OxyContin, Purdue Pharma, Raymond and Beverly Sackler FoundationIssue: March 2019

You Might Also Like:
  • Cigna to End OxyContin Painkiller Coverage, Signs Contract for Alternative
  • U.S. Appeals Court Ruling May Clear Barrier to Generic OxyContin
  • Washington State Sues OxyContin Maker Purdue Pharma
  • New Jersey Sues OxyContin Maker, Links Marketing to Opioid Crisis

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)